Compare BNL & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNL | ALKS |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.5B |
| IPO Year | 2008 | 2012 |
| Metric | BNL | ALKS |
|---|---|---|
| Price | $19.94 | $35.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $20.22 | ★ $43.43 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $454,138,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $7.93 | $24.26 |
| Revenue Next Year | $5.45 | $4.47 |
| P/E Ratio | $82.15 | ★ $25.31 |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $15.28 | $25.17 |
| 52 Week High | $20.48 | $36.56 |
| Indicator | BNL | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 59.55 |
| Support Level | $19.72 | $27.65 |
| Resistance Level | $20.48 | $36.40 |
| Average True Range (ATR) | 0.34 | 1.01 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 52.89 | 60.06 |
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.